EXHIBIT 99.1
QUIGLEY
Contact:
David K. Waldman/John W. Heilshorn Carl Fonash
Lippert Heilshorn & Associates The Quigley Corporation
(212) 838-3777 (267) 880-1111
dwaldman@lhai.com
THE QUIGLEY CORPORATION PROVIDES AN UPDATE OF ITS PROPOSED STOCK
DIVIDEND OF SHARES OF COMMON STOCK OF SUNCOAST NATURALS, INC.
DOYLESTOWN, PA. - JUNE 3, 2004 - THE QUIGLEY CORPORATION (NASDAQ: QGLY) by press
release dated February 19, 2003, announced a distribution of 500,000 shares of
common stock of Suncoast Naturals Inc., held in The Quigley Corporation's name,
to stockholders of record on March 6, 2003. The distribution was made contingent
upon the filing of a registration statement covering these shares by Suncoast
Naturals, Inc. and it being declared effective. The registration statement is
not yet effective, and thus, The Quigley Corporation will be required to set a
new record date and notify its stockholders once the Securities and Exchange
Commission declares the registration statement effective.
ABOUT THE QUIGLEY CORPORATION
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading
developer and marketer of diversified health products including the COLD-EEZE(R)
family of patented zinc gluconate glycine (ZIGG(TM)) lozenges and sugar free
tablets. COLD-EEZE is the only (ZIGG) lozenge proven in two double-blind studies
to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In
addition to Over-The-Counter (OTC) products, the Company has formed Quigley
Pharma Inc. (http://www.QuigleyPharma.com ), a wholly owned ethical
pharmaceutical subsidiary, to introduce a line of naturally-derived patented
prescription drugs. The Quigley Corporation's customers include leading national
wholesalers and distributors, as well as independent and chain food, drug and
mass merchandise stores and pharmacies. The Quigley Corporation makes no
representation that the U.S. Food and Drug Administration or any other
regulatory agency will grant an IND or take any other action to allow the
aforementioned products to be studied or marketed. Furthermore, no claim is made
that the potential medicine discussed here is safe, effective, or approved by
the Food and Drug Administration.
Certain statements in this press release are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995 and involve
known and unknown risk, uncertainties and other factors that may cause the
company's actual performance or achievements to be materially different from the
results, performance or achievements expressed or implied by the forward-looking
statement. Factors that impact such forward-looking statements include, among
others, changes in worldwide general economic conditions, changes in interest
rates, government regulations, and worldwide competition.